⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
accessnewswire.com
CVKD
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
globenewswire.com
CVKD
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
accessnewswire.com
CVKD
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
accessnewswire.com
CVKD
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
globenewswire.com
CVKD
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
globenewswire.com
CVKD
PTCT
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
globenewswire.com
CVKD
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
CVKD
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
globenewswire.com
CVKD